Metal Drugs and the Anticancer Immune Response
Open accessThe DOI matches its Crossref record; 1,300 of the 1,300 references it cites were found in a registry or an index.
Abstract
The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clinical settings. This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects. It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses. Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment. On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Chattopadhyay, S., Dash, S. K., Mahapatra, S. K., Tripathy, S., Ghosh, T., Das, B., Das, D., Pramanik, P., & Roy, S. (2014) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1085-2 · Cited by 50
RetractedChatterjee, S., Mookerjee, A., Basu, J. M., Chakraborty, P., Ganguly, A., Adhikary, A., Mukhopadhyay, D., Ganguli, S., Banerjee, R., Ashraf, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007048 · Cited by 46
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
The capsaicin receptor: a heat-activated ion channel in the pain pathway
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997) · Nature · doi:10.1038/39807 · Cited by 9,107
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Research works printed but not linked: 47
- van der Most R. G., 2005, Discovery Medicine, 5, 265
- Alberts B., 2015, Mol. Biol. Cell
- Seliger B., 1996, Exp. Hematol., 24, 1275
- Fink D., 1996, Cancer Res., 56, 4881
- Yoshikawa A., 1997, Kobe J. Med. Sci., 43, 109
- 10.1007/s00775-018- 1546-8 · doi:10.1007/s00775-018-
- Rosenberg, B. In Advances in Antimicrobial and Antineoplastic Chemotherapy, University Park Press: Baltimore, 1972; Vol. 11.
- 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X · doi:10.1002/(sici)1098-2264(199704)18:4<286::aid-gcc6>3.0.co;2-x
- Dempsey J. L., 1985, Cancer Res., 45, 2873
- Nio Y., 2000, Anticancer Res., 20, 3293
- Qin X., 2010, Cell. Mol. Biol. (Noisy- le-grand), 56, 1366
- Kleinerman E. S., 1980, Cancer Res., 40, 3099
- Lichtenstein A. K., 1986, Cancer Res., 46, 639
- 10.1002/1097-0142(19930215)71:4<1313::AID-CNCR2820710424>3.0.CO;2-# · doi:10.1002/1097-0142(19930215)71:4<1313::aid-cncr2820710424>3.0.co;2-#
- Yamaue H., 1991, J. Clin. Lab. Immunol., 35, 165
- 10.1002/(SICI)1097-0215(19971104)73:3<416::AID-IJC17>3.0.CO;2-A · doi:10.1002/(sici)1097-0215(19971104)73:3<416::aid-ijc17>3.0.co;2-a
- Jiang J., 2006, Anticancer Res., 26, 2237
- Ujiie T., 1989, Jpn. J. Exp. Med., 59, 17
- Maeda K., 2011, Anticancer Res., 31, 4569
- Miller W. H., 2002, Cancer Res., 62, 3893
- 10.1097/CJI.0b013e3181755deb · DOI
- Kreuser E. D., 1992, Semin. Oncol., 19, 73
- Magnarin M., 2000, Anticancer Res., 20, 2939
- Nardon C., 2014, Anticancer Res., 34, 487
- Hashimoto K., 1994, J. Rheumatol., 21, 1020
- Yan A., 1990, J. Rheumatol., 17, 47
- Wang X. D., 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 17, 533
- 10.1371/journal.pone.0100933 · DOI · Paper page
- Korbecki J., 2012, Acta Biochim. Polym., 59, 195
- 10.3109/1547691X.2014.996681 · DOI
- Desoize B., 2004, Anticancer Res., 24, 1529
- Sava G., 1985, Anticancer Res., 5, 249
- Boscolo P., 2004, Ann. Clin. Lab. Sci., 34, 299
- Brewer G. J., 2000, Clin. Cancer Res., 6, 1
- Redman B. G., 2003, Clin. Cancer Res., 9, 1666
- Pan Q., 2003, Mol. Cancer Res., 1, 701
- Lukasewycz O. A., 1982, J. Natl. Cancer Inst., 69, 489
- 10.1515/9783110470734-016 · doi:10.1515/9783110470734-016
- Eriksson M., 2009, Anticancer Res., 29, 11
- Signat B., 2011, Curr. Issues Mol. Biol., 13, 25
- Sonis S. T., 2004, J. Support. Oncol., 2, 21
- 10.1053/sonc.2002.35524 · doi:10.1053/sonc.2002.35524 · Paper page
- Juhn S. K., 2001, Int. Tinnitus J., 7, 72
- Boussios S., 2012, Ann. Gastroenterol., 25, 106
- Takeyama K., 2000, Int. J. Hematol., 71, 144
- Giles F. J., 1994, Curr. Opin. Hematol., 1, 256
- Lu J., 2017, Ochsner J., 17, 379
Cited by
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Toxicity of gold nanoparticles (AuNPs): A review
Sani, A., Cao, C., & Cui, D. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.100991 · Cited by 454
Classification of Metal-Based Drugs according to Their Mechanisms of Action
Boros, E., Dyson, P. J., & Gasser, G. (2020) · Chem · doi:10.1016/j.chempr.2019.10.013 · Cited by 437
New Designs for Phototherapeutic Transition Metal Complexes
Imberti, C., Zhang, P., Huang, H., & Sadler, P. J. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201905171 · Cited by 443
The immune microenvironment in cartilage injury and repair
Li, M., Yin, H., Yan, Z., Li, H., Wu, J., Wang, Y., Wei, F., Tian, G., Ning, C., Li, H., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.12.006 · Cited by 403
Alessio, E., & Messori, L. (2019) · Molecules · doi:10.3390/molecules24101995 · Cited by 385
Wang, L., Guan, R., Xie, L., Liao, X., Xiong, K., Rees, T. W., Chen, Y., Ji, L., & Chao, H. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202013987 · Cited by 289
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Copper in tumors and the use of copper-based compounds in cancer treatment
da Silva, D. A., De Luca, A., Squitti, R., Rongioletti, M., Rossi, L., Machado, C. M. L., & Cerchiaro, G. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111634 · Cited by 241
Ruthenium-Based Photoactivated Chemotherapy
Bonnet, S. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01135 · Cited by 228
Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses
Peng, K., Zheng, Y., Xia, W., & Mao, Z.-W. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00757f · Cited by 188
Strategies for the development of metalloimmunotherapies
Sun, X., Zhou, X., Shi, X., Abed, O. A., An, X., Lei, Y. L., & Moon, J. J. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01221-7 · Cited by 163
“These DAMP molecules can further activate APCs (such as dendritic cells) in the tumour microenvironment and prime T cell immune responses against cancer 20 .”
The gold complex auranofin: new perspectives for cancer therapy
Abdalbari, F. H., & Telleria, C. M. (2021) · Discover Oncology · doi:10.1007/s12672-021-00439-0 · Cited by 167
“for the treatment of active progressive rheumatoid arthritis, and is commercialized under the brand name of Ridaura [9].”
BackgroundInfluentialPeng, K., Liang, B.-B., Liu, W., & Mao, Z.-W. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214210 · Cited by 162
Zheng, K., Sui, B., Ilyas, K., & Boccaccini, A. R. (2020) · Materials Horizons · doi:10.1039/d0mh01498b · Cited by 144
Tham, M. J. R., Babak, M. V., & Ang, W. H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008604 · Cited by 143
Kurtuldu, F., Mutlu, N., Boccaccini, A. R., & Galusek, D. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.12.034 · Cited by 140
Tu, L., Li, C., Ding, Q., Sharma, A. K., Li, M., Li, J., Kim, J. S., & Sun, Y. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c13224 · Cited by 132
Ling, Y., Xia, X., Liang, H., Wang, W., Zhang, H., Liu, L., Liu, W., Li, Z., Tan, C., & Mao, Z. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202210988 · Cited by 134
Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion
Bekeschus, S., Clemen, R., Nießner, F., Sagwal, S. K., Freund, E., & Schmidt, A. (2020) · Advanced Science · doi:10.1002/advs.201903438 · Cited by 132
Rationally Designed Redox-Active Au(I) N-Heterocyclic Carbene: An Immunogenic Cell Death Inducer
Sen, S., Hufnagel, S., Maier, E. Y., Aguilar, I., Selvakumar, J., DeVore, J. E., Lynch, V. M., Arumugam, K., Cui, Z., Sessler, J. L., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09753 · Cited by 126
Oxidative Stress in Cancer Therapy: Friend or Enemy?
Azmanova, M., & Pitto‐Barry, A. (2022) · ChemBioChem · doi:10.1002/cbic.202100641 · Cited by 131
Copper in cancer: From pathogenesis to therapy
Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114791 · Cited by 128
Wang, L., Karges, J., Wei, F., Xie, L., Chen, Z., Gasser, G., Ji, L., & Chao, H. (2023) · Chemical Science · doi:10.1039/d2sc06675k · Cited by 119
“20 26 – 28 Brabec and co-workers re-ported on a Pt( IV ) prodrug that could be reduced into the respective Pt( II ) species upon irradiation, causing the release of damage-associated molecular patterns and cell death by ICD.”
The Role of Tumour Metabolism in Cisplatin Resistance
Wang, L., Zhao, X., Fu, J., Xu, W., & Yuan, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.691795 · Cited by 133
“Current treatments for tumours include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy (McCarthy, 2006; Englinger et al., 2019).”
BackgroundKaur, P., Johnson, A., Northcote‐Smith, J., Lü, C., & Suntharalingam, K. (2020) · ChemBioChem · doi:10.1002/cbic.202000553 · Cited by 108
Metal‐based smart nanosystems in cancer immunotherapy
Luo, Y., He, X., Du, Q., Xu, L., Xu, J., Wang, J., Zhang, W., Zhong, Y., Guo, D., Liu, Y., et al. (2024) · Exploration · doi:10.1002/exp.20230134 · Cited by 112
Recent progress in the development of organometallics for the treatment of cancer
Murray, B. S., & Dyson, P. J. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.001 · Cited by 105
“Recent studies have also highlighted the considerable potential of platinum-based drugs combined with immunotherapy [40].”
Backgroundde Paiva, R. E. F., Neto, A. M., Santos, I. A., Jardim, A. C. G., Corbi, P. P., & Bergamini, F. R. G. (2020) · Dalton Transactions · doi:10.1039/d0dt02478c · Cited by 106
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance
Valente, A., Podolski-Renić, A., Poetsch, I., Filipović, N. R., López, Ó., Turel, I., & Heffeter, P. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100778 · Cited by 107
Self-citationChemical Design of Magnetic Nanomaterials for Imaging and Ferroptosis-Based Cancer Therapy
Xu, W., Guan, G., Yue, R., Dong, Z., Lei, L., Kang, H., & Song, G. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00546 · Cited by 107
Xiong, X., Huang, K.-B., Wang, Y., Cao, B., Luo, Y., Chen, H. W., Yang, Y. H., Long, Y., Liu, M., Chan, A. S. C., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02435 · Cited by 97
Zhao, H., Chen, H., Guo, Z., Zhang, W., Yu, H., Zhuang, Z., Zhong, H., & Liu, Z. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.124314 · Cited by 95
Oxaliplatin and its derivatives – An overview
O'Dowd, P., Sutcliffe, D. F., & Griffith, D. M. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215439 · Cited by 102
Rausch, M., Dyson, P. J., & Nowak-Sliwinska, P. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900042 · Cited by 94
Molecular and Cellular Mechanisms of Cytotoxic Activity of Vanadium Compounds against Cancer Cells
Kowalski, S., Wyrzykowski, D., & Inkielewicz‐Stępniak, I. (2020) · Molecules · doi:10.3390/molecules25071757 · Cited by 90
Cai, L., Wang, Y., Chen, Y., Chen, H., Yang, T., Zhang, S., Guo, Z., & Wang, X. (2023) · Chemical Science · doi:10.1039/d2sc06036a · Cited by 91
Lai, H., Zeng, D., Liu, C., Zhang, Q., Wang, X., & Chen, T. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119377 · Cited by 88
Recent Advances of Gold Compounds in Anticancer Immunity
Yue, S., Luo, M., Liu, H., & Wei, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00543 · Cited by 90
“Type I ICD inducers exert multiple cytotoxic effects and trigger ER stress as a secondary mode of action, while type II inducers mediates ROS-related ER-stress as the main mechanism of action (Garg et al., 2015).”
BackgroundInfluentialYu, C., Wang, Z., Sun, Z., Zhang, L., Zhang, W., Xu, Y., & Zhang, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00950 · Cited by 89
Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II
Xiong, K., Qian, C., Yuan, Y., Wei, L., Liao, X., He, L., Rees, T. W., Chen, Y., Wan, J., Ji, L., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006089 · Cited by 84
Gojo, J., Pavelka, Z., Zapletalová, D., Schmook, M. T., Mayr, L., Madlener, S., Kýr, M., Vejmělková, K., Smrčka, M., Czech, T., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01436 · Cited by 83
“Immunotherapy has revolutionized oncology in the past years and resulted in substantial improvement of treatment outcomes in certain tumor types (47).”
BackgroundLevina, A., Vieira, A. P., Wijetunga, A. R., Kaur, R., Koehn, J. T., Crans, D. C., & Lay, P. A. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005458 · Cited by 82
Light‐Driven Cascade Mitochondria‐to‐Nucleus Photosensitization in Cancer Cell Ablation
Wang, K., Liu, L., Qi, G., Chao, X., Ma, W., Yu, Z., Pan, Q., Mao, Z., & Liu, B. (2021) · Advanced Science · doi:10.1002/advs.202004379 · Cited by 77
Agonists and Inhibitors of the cGAS-STING Pathway
Yu, X., Cai, L., Yao, J., Li, C., & Wang, X. (2024) · Molecules · doi:10.3390/molecules29133121 · Cited by 80
“Although metal-based cGAS-STING agonists have demonstrated promising activities, the clinical application of these compounds is limited by their side e ff ects [98].”
BackgroundInfluentialDinda, R., Garribba, E., Sanna, D., Crans, D. C., & Pessoa, J. C. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00475 · Cited by 81
Hydrazones, hydrazones-based coinage metal complexes, and their biological applications
Tafere, D. A., Gebrezgiabher, M., Elemo, F., Sani, T., Atisme, T. B., Ashebr, T. G., & Ahmed, I. N. (2025) · RSC Advances · doi:10.1039/d4ra07794f · Cited by 73
Farrer, N. J., & Griffith, D. M. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.12.001 · Cited by 74
New Designs for Phototherapeutic Transition Metal Complexes
Imberti, C., Zhang, P., Huang, H., & Sadler, P. J. (2019) · Angewandte Chemie · doi:10.1002/ange.201905171 · Cited by 73
Gold nanoparticles in chemo-, immuno-, and combined therapy: review [Invited]
Dykman, L. A., & Khlebtsov, N. G. (2019) · Biomedical Optics Express · doi:10.1364/boe.10.003152 · Cited by 75
Huang, K.-B., Wang, F.-Y., Feng, H.-W., Luo, H., Long, Y., Zou, T., Chan, A. S. C., Liu, R., Zou, H., Chen, Z., et al. (2019) · Chemical Communications · doi:10.1039/c9cc06563f · Cited by 69
A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt IV Complexes under Physiological Conditions
Kastner, A., Poetsch, I., Mayr, J., Burda, J. V., Roller, A., Heffeter, P., Keppler, B. K., & Kowol, C. R. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201900682 · Cited by 76
Self-citationInduction of immunogenic cell death in cancer cells by a photoactivated platinum( iv ) prodrug
Novohradský, V., Prachařová, J., Kašpárková, J., Imberti, C., Bridgewater, H. E., Sadler, P. J., & Brabec, V. (2020) · Inorganic Chemistry Frontiers · doi:10.1039/d0qi00991a · Cited by 69
Wang, J., Nie, J.-J., Guo, P., Yan, Z., Yu, B., & Bu, W. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11013 · Cited by 66
Nucleolar Stress Induction by Oxaliplatin and Derivatives
Sutton, E. C., McDevitt, C. E., Prochnau, J. Y., Yglesias, M. V., Mroz, A. M., Yang, M., Cunningham, R. M., Hendon, C. H., & DeRose, V. J. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10319 · Cited by 69
Fronik, P., Poetsch, I., Kastner, A., Mendrina, T., Hager, S., Hohenwallner, K., Schueffl, H. H., Herndler‐Brandstetter, D., Koellensperger, G., Rampler, E., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00770 · Cited by 67
Self-citationSumithaa, C., & Ganeshpandian, M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01027 · Cited by 69
Fan, Q., Kuang, L., Wang, F., Yin, Y., Dong, Z., Tian, N., Wang, J., Yin, T., & Wang, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c01253 · Cited by 70
Li, C., Tu, L., Xu, Y., Li, M., Du, J., Stang, P. J., Sun, Y., & Sun, Y. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202406392 · Cited by 77
Vigueras, G., Marková, L., Novohradský, V., Marco, A., Cutillas, N., Kostrhunová, H., Kašpárková, J., Ruiz, J., & Brabec, V. (2021) · Inorganic Chemistry Frontiers · doi:10.1039/d1qi00856k · Cited by 67
Stimuli‐Responsive Metal Complexes for Biomedical Applications
Amarsy, I., Papot, S., & Gasser, G. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202205900 · Cited by 67
A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
Fronik, P., Gutmann, M., Vician, P., Stojanovic, M., Kastner, A., Heffeter, P., Pirker, C., Keppler, B. K., Berger, W., & Kowol, C. R. (2022) · Communications Chemistry · doi:10.1038/s42004-022-00661-z · Cited by 63
Self-citationSu, S., Chen, Y., Zhang, P., Ma, R., Zhang, W., Liu, J., Li, T., Niu, H., Cao, Y., Hu, B., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114680 · Cited by 64
Liao, L.-S., Chen, Y., Hou, C., Liu, Y.-H., Su, G., Liang, H., & Chen, Z. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00603 · Cited by 61
Huang, K.-B., Wang, F.-Y., Lu, Y., Yang, L.-M., Long, N., Wang, S., Xie, Z., Levine, M. S., Zou, T., Sessler, J. L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404668121 · Cited by 61
Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic
Caiado, J., Brás, R., Paulino, M., Costa, L., & Castells, M. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.04.017 · Cited by 58
Bioengineering of nano metal-organic frameworks for cancer immunotherapy
Chong, G., Zang, J., Han, Y., Su, R., Weeranoppanant, N., Dong, H., & Li, Y. (2020) · Nano Research · doi:10.1007/s12274-020-3179-9 · Cited by 56
Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer
Podolski-Renić, A., Gašparović, A. Č., Valente, A., López, Ó., Nunes, J. H. B., Kowol, C. R., Heffeter, P., & Filipović, N. R. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116363 · Cited by 65
Self-citationAllemailem, K. S., Almatroudi, A., Alrumaihi, F., Almatroodi, S. A., Alkurbi, M. O., Basfar, G. T., Rahmani, A. H., & Khan, A. A. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s321343 · Cited by 55
Xia, T., Xia, Z., Tang, P., Fan, J., & Peng, X. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c13095 · Cited by 52
Feng, T., Tang, Z., Shu, J., Wu, X., Jiang, H., Chen, Z., Chen, Y., Ji, L., & Chao, H. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202405679 · Cited by 54
Metal Complexes of Oxadiazole Ligands: An Overview
Salassa, G., & Terenzi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143483 · Cited by 52
“There is, in fact, a big need in cancer chemotherapy (and immunotherapy) to find new metal compounds with improved efficacy and less side effects than the clinically used platinum drugs [53].”
BackgroundSelf-citationSubcellular Duplex DNA and G‐Quadruplex Interaction Profiling of a Hexagonal Pt II Metallacycle
Domarco, O., Kieler, C., Pirker, C., Dinhof, C., Englinger, B., Reisecker, J. M., Timelthaler, G., García, M. D., Peinador, C., Keppler, B. K., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201900934 · Cited by 51
Self-citationA focus on the biological targets for coinage metal-NHCs as potential anticancer complexes
Guarra, F., Pratesi, A., Gabbiani, C., & Biver, T. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111355 · Cited by 61
Marotta, C., Giorgi, E., Binacchi, F., Cirri, D., Gabbiani, C., & Pratesi, A. (2023) · Inorganica Chimica Acta · doi:10.1016/j.ica.2023.121388 · Cited by 55
“Strikingly, in further experiments this animal showed the development of some sort of antitumor memory or vaccination, as he rejected the novel living administrated CT26 cells [197,198].”
Li, J., Zeng, L., Wang, Z., Chen, H., Fang, S., Wang, J., Cai, C., Xing, E., Liao, X., Li, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100245 · Cited by 50
Highlighting the roles of transition metals and speciation in chemical biology
Kostenkova, K., Scalese, G., Gambino, D., & Crans, D. C. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102155 · Cited by 49
Sarkar, A., Novohradský, V., Maji, M., Babu, T., Marková, L., Kostrhunová, H., Kašpárková, J., Gandin, V., Brabec, V., & Gibson, D. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202310774 · Cited by 50
Chemical and Biological Evaluation of Thiosemicarbazone-Bearing Heterocyclic Metal Complexes
Matesanz, A. I., Melones-Herrero, J., & Quiroga, A. G. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201022144004 · Cited by 49
Wang, L., Guan, R., Xie, L., Liao, X., Xiong, K., Rees, T. W., Chen, Y., Ji, L., & Chao, H. (2021) · Angewandte Chemie · doi:10.1002/ange.202013987 · Cited by 53
Recent Progress in Photodynamic Immunotherapy with Metal‐Based Photosensitizers
Xiong, K., Wei, F., Chen, Y., Ji, L., & Chao, H. (2022) · Small Methods · doi:10.1002/smtd.202201403 · Cited by 52
Li, W., Li, S., Zhang, Z., Xu, G., Man, X., Yang, F., & Liang, H. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00248 · Cited by 49
Mármol, I., Castellnou, P., Alvarez, R., Gimeno, M. C., Rodriguez‐Yoldi, M. J., & Cerrada, E. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111661 · Cited by 50
del Solar, V., & Contel, M. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.110780 · Cited by 50
Flavin Bioorthogonal Photocatalysis Toward Platinum Substrates
Gurruchaga‐Pereda, J., Martínez‐Martínez, V., Rezabal, E., López, X., Garino, C., Mancin, F., Cortajarena, A. L., & Salassa, L. (2019) · ACS Catalysis · doi:10.1021/acscatal.9b02863 · Cited by 50
Research Progress of Metal Anticancer Drugs
Bai, Y., Aodeng, G., Ga, L., Hai, W., & Ai, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122750 · Cited by 48
“Besides their extensively researched cytotoxic and anticancer properties, metal-based drugs are commonly employed in cancer-immune interactions and have the ability to reverse pivotal aspects of immune evasion [10].”
BackgroundMetal complex-based liposomes: Applications and prospects in cancer diagnostics and therapeutics
Wang, Z., Li, J., Lin, G., He, Z., & Wang, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.012 · Cited by 49
Targeting of the intracellular redox balance by metal complexes towards anticancer therapy
Murillo, M. I., Gaiddon, C., & Lagadec, R. L. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.967337 · Cited by 47
Cai, L., Wang, Y., Chen, H., Tan, Y., Yang, T., Zhang, S., Guo, Z., & Wang, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00836 · Cited by 47
Targeting translation: a promising strategy for anticancer metallodrugs
Ortega, E., Vigueras, G., Ballester, F. J., & Ruiz, J. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214129 · Cited by 47
Organometallic nucleosides—Synthesis, transformations, and applications
Kowalski, K. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213705 · Cited by 44
New opportunities for immunomodulation of the tumour microenvironment using chemical tools
Su, J., Li, W., & Li, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00486k · Cited by 47
Schueffl, H. H., Theiner, S., Hermann, G., Mayr, J., Fronik, P., Groza, D., Schoonhoven, S., Galvez, L., Sommerfeld, N. S., Schintlmeister, A., et al. (2021) · Chemical Science · doi:10.1039/d1sc03311e · Cited by 43
Self-citationSahu, G., Patra, S. A., Lima, S., Das, S., Görls, H., Plass, W., & Dinda, R. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202202694 · Cited by 48
Huang, S., Gao, Y., Li, H., Wang, R., Zhang, X., Wang, X., Huang, D., Zhang, L., Santos, H. A., Yin, Z., et al. (2023) · Advanced Materials · doi:10.1002/adma.202310979 · Cited by 49
Ni(II) curcumin complexes for cellular imaging and photo-triggered in vitro anticancer activity
Banaspati, A., Raza, M. K., & Goswami, T. K. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112632 · Cited by 42
Ribeiro, G. H., Guedes, A. P. M., de Oliveira, T. D., de Correia, C. R. S. T. B., Colina–Vegas, L., Lima, M. A., Nóbrega, J. A., Cominetti, M. R., Rocha, F. V., Ferreira, A. G., et al. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c01835 · Cited by 43
Tang, L., Cai, D., Qin, M., Lu, S., Hu, M.-H., Ruan, S., Jin, G., & Wang, Z. (2019) · ACS Omega · doi:10.1021/acsomega.9b03381 · Cited by 41
“8,14,15 For example, it has been shown that oxaliplatin is able to cause ribosome biogenesis stress and nucleolar stress, which might lead to its di ff erent clinical applications and side e ff ects pro fi les.”
Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy
Chauhan, A., Khan, T. A., & Omri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158037 · Cited by 43
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
Metadata
- Authors
- Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W.
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- University of Vienna (AT)
- Corresponding author
- Berger, Walter
- ORCID
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-29
- Volume
- 119
- Issue
- 2
- Pages
- 1519-1624
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2903051221
- Cited by
- 355
- References
- 1,298
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 47 · 2023: 51 · 2022: 49 · 2021: 45 · 2020: 53 · 2019: 38
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- FP7 People: Marie-Curie Actions (609431)
- Universit?t Wien
- Medizinische Universit?t Wien
- Johanna Mahlke, geb. Obermann-Stiftung zur F?rderung der Krebsforschung an der Universit?t Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- metal-based anticancer agents, antitumor immunity, immune surveillance, immune evasion, cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, innate and adaptive immunity
- MeSH terms
- Gastrointestinal Microbiome, Antineoplastic Agents, Humans, Immunity, Innate, Immunotherapy, Lymphocytes, Metals, Neoplasms, Nanoparticles, Coordination Complexes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.